LPTN Share Price

Open 3.02 Change Price %
High 3.02 1 Day -0.08 -2.66
Low 2.93 1 Week 0.00 0.00
Close 2.93 1 Month 0.00 0.00
Volume 14706 1 Year 1.04 55.03
52 Week High 4.05
52 Week Low 1.70
LPTN Important Levels
Resistance 2 3.01
Resistance 1 2.98
Pivot 2.96
Support 1 2.88
Support 2 2.85
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.16 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
AEZS 2.34 129.41%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AEZS 2.34 129.41%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CPSL 0.11 22.22%
VRTX 159.69 20.83%
ENG 1.40 19.66%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ZOOM 0.02 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CPWR 3.00 -52.00%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
QKLS 0.11 -47.62%
More..

Lpath, Inc. (NASDAQ: LPTN)

LPTN Technical Analysis 3
As on 29th Dec 2016 LPTN Share Price closed @ 2.93 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.62 & Buy for SHORT-TERM with Stoploss of 2.73 we also expect STOCK to react on Following IMPORTANT LEVELS.
LPTN Target for July
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
LPTN Other Details
Segment EQ
Market Capital 68592976.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.lpath.com
LPTN Address
LPTN
4025 Sorrento Valley Boulevard
San Diego, CA 92121
United States
Phone: 858-678-0800
Fax: 858-678-0900
LPTN Latest News
Interactive Technical Analysis Chart Lpath, Inc. ( LPTN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Lpath, Inc.
LPTN Business Profile
Lpath, Inc. (Lpath) is a biotechnology company focused on the discovery and development of bio-active lipid-targeted monoclonal antibody (mAb) therapeutics. The Company has three product candidates, iSONEP, ASONEP and Lpathomab. The Company's program, iSONEP, is a mAb against Sphingosine-1-Phosphate (S1P). As of December 31, 2012, it was in phase-II clinical trials for wet Age-Related Macular Degeneration. The Company is also advancing ASONEP, the systemic formulation of the mAb to S1P. ASONEP has completed a phase-I clinical trial and is entering phase-II clinical trials in Renal Cell Carcinoma. Lpath's third product candidate, Lpathomab, is a mAb to the bioactive lipid, Lysophosphatidic Acid (LPA). The Company also applies its technology platform, ImmuneY2, to discovering mAbs to new bioactive lipid targets.